Login to Your Account



Drug development constituents still wrangling over how to price biopharma innovation

By Marie Powers
News Editor

Monday, October 31, 2016

CLEVELAND – The biopharma industry has found itself between a rock and hard place, or at least that was the premise for a panel of experts across the drug development supply chain that convened at the 2016 Medical Innovation Summit sponsored by Cleveland Clinic Innovations.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription